Categories: IT and Telecommunications
Assisted reproductive technology (ART) is a method of conceiving a child by surgically removing a female's eggs and combining them with sperm in a laboratory under specialised conditions, then implanting them in the female's ovaries or the ovaries of a surrogate mother. Due to increased infertility concerns among women and its usefulness in preserving the genetic connection of a kid with his or her biological parents, the assisted reproductive technology business is gaining steam.
Increased infertility incidences, owing to factors such as increased alcohol use, smoking, obesity, and stress, are expected to drive the assisted reproductive technology market throughout the forecast period. According to the National Institutes of Mental Health, one out of every 75 persons suffers from panic disorder and mental health problems. The global assisted reproductive technology market is predicted to develop due to a growing acceptability of this technique among various populations, as well as recent advancements in the industry. However, the social stigma associated with these technologies, as well as high treatment costs, may limit the commercial expansion of assisted reproductive technology in underdeveloped nations. In India, for example, IVF treatment costs typically vary from $1,400 to $5,500 each treatment cycle.
Because of its greater success rates, ease of process, reimbursement rules, and availability of a number of IVF centres and reproductive clinics, the in-vitro fertilization-embryo transfer method is predicted to hold a significant proportion of income generating among the numerous technologies available. According to the CDC's Fertility Clinic Success Rates report from 2016, a total of 263,577 ART cycles were done at 463 reporting clinics in the United States (in 2016), with 65,996 resulting in live births (delivery of one or more living children) and 76,930 resulting in live born infants.
Fresh non-donor segment is projected to increase greatly in the procedure segment because to their efficacy in preserving the genetic connection between the child and biological parents. According to the Centers for Disease Control and Prevention (CDC), the fresh non-donor method was the most often utilised ART treatment in 2015, accounting for 39.3 percent of all assisted reproductive technology cycles conducted. The second most popular treatment was frozen non-donor segment, which contributed for 30.1 percent of all ART cycles.
The assisted reproductive technology market is split into hospitals and fertility clinics. Due to the global increase in the number of fertility clinics, specialised fertility clinics are likely to hold the largest revenue share in the global assisted reproductive technology market. Fertility clinics such as GATJC Fertlity Center, IVF Spain, and Embryolab are present, ensuring their future expansion in the assisted reproductive technology sector.
Because of the advanced medical infrastructure in this area, North America and Europe are likely to hold a significant revenue share in the worldwide assisted reproductive technology market. According to the CDC, roughly 1.5 million IVF cycles are performed worldwide each year, with Europe accounting for 55 percent of all reported IVF cycles. Consumer awareness is growing, and individuals in these places have a lot of money to spend, thus regional markets will continue to grow.
Due to greater social acceptance of ART in the region, as well as an increase in infertility cases in countries like India, South Korea, and Japan, the Asia Pacific market is predicted to develop significantly over the forecast period. The total fertility rate (TFR) in India fell by 22.73 percent from 2.7 in 2005-06 to 2.2 in 2015-16, according to the Open Government Data Platform (OGD).
Merck, Nidacon International AB, Laboratoire CCD, Parallabs, Inc., CooperSurgical, Hamilton Thorne, Esco Micro Private Limited, Inc., Bloom IVF Center, Cosmos Biomedical Limited, Irvine Scientific, Ferring Pharmaceuticals, and Nikon Corporation are some of the major players in the assisted reproductive technology market. NMC Health, a UAE healthcare conglomerate, purchased Fakih IVF in its entirety on January 28, 2018, in order to expand their business. Instituto Valenciano de Infertilidad (IVI) announced their arrival in the United States in February 2017 by negotiating a deal with Reproductive Medicine Associates of New Jersey (RMANJ).